Inclusion Criteria:  Age >= 18 years at time of signing informed consent form ECOG performance status of 0 or 1 Patients with a histologically or cytologically proven diagnosis of a locally advanced, recurrent, or metastatic incurable solid tumor for which standard therapy either does not exist or has proven ineffective or intolerable Patients with documented RAS alterations positive solid tumors Patients with measurable disease per RECIST v1.1  Exclusion Criteria:  Significant cardiovascular disease, such as New York Heart Association (NYHA) cardiac disease (Class II or greater), unstable angina, or myocardial infarction within the previous 6 months or unstable arrhythmias within the previous 3 months Patients with primary central nervous system (CNS) malignancy, untreated CNS metastases requiring any anti-tumor treatment, or active CNS metastases Patients with current severe, uncontrolled systemic disease (including, but not limited to, clinically significant cardiovascular disease, pulmonary disease, or renal disease, ongoing or active infection) Patients with a history or complication of interstitial lung disease (ILD)